Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2026
상품코드:1957908
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈관내피성장인자(VEGF) 억제제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 113억 달러에서 2026년에는 121억 1,000만 달러에 이르고, CAGR 7.2%로 성장할 전망입니다. 지난 수년간의 성장에는 암 및 망막 질환의 발생률 증가, 단일클론항체 등장 이전에는 치료 옵션이 제한적이었던 점, 항혈관 신생 요법의 이점에 대한 인식 증가, 의사들의 표적 치료법 채택 증가, 1세대 VEGF 억제제의 규제 당국 승인 등이 주요 요인으로 작용한 것으로 보입니다.
혈관내피성장인자(VEGF) 억제제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 162억 3,000만 달러에 이르고, CAGR은 7.6%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 차세대 VEGF 억제제 개발, 면역종양학 분야의 병용요법 확대, 맞춤의료 도입 증가, 안과 분야의 의약품 개발 투자 증가, 디지털 모니터링과 AI 기반 치료 평가의 통합 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 종양학 및 안과 영역에서 VEGF 억제제의 채택 확대, 단클론 항체 및 항혈관 신생 치료제 개발 증가, 유리체강 내 및 정맥 내 투여 경로의 성장, 개인 맞춤형 의료 및 표적 치료 접근법 확대, 신규 VEGF 억제제 관련 임상시험 및 연구 증가를 들 수 있습니다.
암과 노인황반변성의 유병률 증가는 향후 몇 년 동안 VEGF 억제제 시장의 성장을 견인할 것으로 예측됩니다. 암은 비정상적인 세포의 통제할 수 없는 증식을 특징으로 하며, 신체의 다른 부위로 전이될 수 있습니다. 한편, 노인황반변성은 망막 중심부의 열화를 일으켜 시력 장애를 유발하는 질환입니다. 이러한 질병 발생률 증가는 고령화 및 생활습관 관련 위험 요인에 의해 촉진되고 있으며, 효과적인 치료법 및 의료 개입에 대한 수요가 증가하고 있습니다. 혈관내피성장인자(VEGF) 억제제는 종양의 성장과 확산에 필요한 새로운 혈관 형성을 억제하여 암을 치료하고, 종양의 진행과 전이를 억제합니다. 예를 들어, 세계보건기구(WHO) 보고서에 따르면 2024년 2월 기준 2050년까지 신규 암 환자 수는 3,500만 명을 넘어설 것으로 예상되며, 이는 2022년 추정 환자 수 2,000만 명에서 77% 증가한 수치입니다. 따라서 암과 황반변성의 유병률 증가는 VEGF 억제제 시장의 성장에 기여하고 있습니다.
VEGF 억제제 시장에서 사업을 전개하고 있는 주요 기업들은 투여 간격을 연장하고 환자의 치료 부담을 최소화하기 위한 고농도 유리체강내 주사제 등 첨단 안과 치료법 개발에 주력하고 있습니다. 고농도 유리체강내주사제는 1회당 유효성분 함량을 증량하여 치료 효과는 유지하면서 주사 횟수를 줄여 환자의 부담을 줄였습니다. 예를 들어, 2024년 4월 일본 제약회사 산텐제약은 일본 제약 및 생명과학 기업 바이엘과 공동으로 114.3 mg/mL 농도의 안과용 VEGF 억제제 아이리아 8mg 유리체강내주사제를 출시했습니다. 이러한 치료법은 시력 상실을 유발할 수 있는 노화성 황반변성(nAMD), 당뇨병성 황반부종(DME) 등의 질환에 대한 표준 치료법입니다. 기존 제품보다 고농축된 아이리아 8mg은 투여 간격을 최대 16주까지 연장할 수 있어 안전성과 유효성을 유지하면서 유리체강내 주사 빈도를 줄일 수 있습니다. 이번 혁신은 환자의 치료 부담을 줄이고 새로운 표준 치료법을 확립하는 한편, 첨단 안과 치료에 대한 접근성 확대라는 전략적 목표 달성을 지원하기 위한 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
A VEGF inhibitor is a substance that blocks programmed cell death by functioning as an anti-apoptotic factor for hematopoietic cells. VEGF enhances vascular permeability, which can facilitate tumor spread through the bloodstream and support increased oxygen and nutrient supply to tumors.
The primary types of vascular endothelial growth factor (VEGF) inhibitors include Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a drug used to treat wet age-related macular degeneration (AMD) and is also applied in managing diabetic eye diseases and other retinal disorders. It is injected into the eye to help slow vision loss associated with specific conditions. These inhibitors are administered through oral and intravenous routes and are used across applications such as oncology, ophthalmology, and others.
Tariffs have impacted the VEGF inhibitor market by increasing the cost of imported biologics, monoclonal antibodies, and administration devices, affecting supply chains and treatment affordability. Segments like oncology and ophthalmology drugs are most affected, particularly in North America and Europe, which rely heavily on imports. While tariffs have raised treatment costs and caused potential delays in therapy availability, they have also encouraged local manufacturing, investment in domestic R&D, and innovation in cost-effective VEGF inhibitor therapies.
The vascular endothelial growth factor (vegf) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (vegf) inhibitor market statistics, including vascular endothelial growth factor (vegf) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (vegf) inhibitor market share, detailed vascular endothelial growth factor (vegf) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (vegf) inhibitor industry. This vascular endothelial growth factor (vegf) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vascular endothelial growth factor (vegf) inhibitor market size has grown strongly in recent years. It will grow from $11.3 billion in 2025 to $12.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising incidence of cancer and retinal disorders, limited treatment options before monoclonal antibodies, growing awareness of anti-angiogenic therapy benefits, increasing physician adoption of targeted therapies, regulatory approvals of first-generation vegf inhibitors.
The vascular endothelial growth factor (vegf) inhibitor market size is expected to see strong growth in the next few years. It will grow to $16.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of next-generation vegf inhibitors, expansion in immuno-oncology combinations, increasing adoption of personalized medicine, rising investments in ophthalmic drug development, integration of digital monitoring and AI-based treatment assessment. Major trends in the forecast period include rising adoption of vegf inhibitors in oncology and ophthalmology, increasing development of monoclonal antibodies and anti-angiogenic therapies, growth in intravitreal and intravenous administration routes, expansion of personalized medicine and targeted therapy approaches, increasing clinical trials and research for novel vegf inhibitors.
The increasing prevalence of cancer and macular degeneration is anticipated to drive the growth of the VEGF inhibitor market in the coming years. Cancer is a condition characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body, while macular degeneration is a disorder that causes deterioration of the central region of the retina, leading to vision impairment. The rising occurrence of these conditions is driven by factors such as an aging population and lifestyle-related risks, resulting in greater demand for effective treatment options and healthcare interventions. Vascular endothelial growth factor (VEGF) inhibitors help address cancer by preventing the formation of new blood vessels required for tumor growth and spread, thereby limiting tumor progression and metastasis. For example, in February 2024, according to the World Health Organization, a Switzerland-based international organization focused on global health policy and public health initiatives, more than 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer and macular degeneration is contributing to the growth of the VEGF inhibitor market.
Key companies operating in the VEGF inhibitor market are emphasizing the development of advanced ophthalmic therapies, including higher-concentration intravitreal injection formulations designed to extend dosing intervals and minimize treatment burden for patients. Higher-concentration intravitreal injection solutions contain increased levels of the active drug per dose, allowing for fewer injections while preserving therapeutic effectiveness and reducing patient burden. For instance, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, in collaboration with Bayer Yakuhin, a Japan-based pharmaceutical and life sciences company, launched the ophthalmic VEGF inhibitor Eylea 8 mg solution for intravitreal injection at a concentration of 114.3 mg/mL. These therapies are standard treatments for conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both of which can lead to vision loss. Eylea 8 mg, featuring a higher concentration than earlier versions, enables an extended dosing interval of up to 16 weeks, decreasing the frequency of intravitreal injections while maintaining safety and efficacy. This innovation is intended to reduce the treatment burden on patients and establish a new standard of care, while also supporting the strategic goal of expanding access to this advanced ophthalmic therapy.
In January 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired the worldwide license for fruquintinib, a highly selective oral VEGFR1/2/3 tyrosine kinase inhibitor, from HUTCHMED Limited for an undisclosed sum. Under the terms of the agreement, Takeda obtained exclusive global rights to develop and commercialize fruquintinib for all indications and regions outside mainland China, Hong Kong, and Macau. HUTCHMED Limited is a China-based pharmaceutical company specializing in the development of vascular endothelial growth factor receptor (VEGFR) 1/2/3-targeted therapies.
Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.
North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2025. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the vascular endothelial growth factor (vegf) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses vascular endothelial growth factor (vegf) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vascular endothelial growth factor (vegf) inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vascular endothelial growth factor (vegf) inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drugs Type: Avastin; Tecentriq; Lucentis; Cometriq; Eylea; Other Drug Types
2) By Route Of Administration: Oral; Intravenous; Intravitreal
3) By Application: Oncology; Ophthalmology; Other Applications
Subsegments:
1) By Avastin: Oncology Applications; Ophthalmology Applications
2) By Tecentriq: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Bladder Cancer; Triple-Negative Breast Cancer
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Vegf Inhibitors In Oncology And Ophthalmology
4.2.2 Increasing Development Of Monoclonal Antibodies And Anti-Angiogenic Therapies
4.2.3 Growth In Intravitreal And Intravenous Administration Routes
4.2.4 Expansion Of Personalized Medicine And Targeted Therapy Approaches
4.2.5 Increasing Clinical Trials And Research For Novel Vegf Inhibitors
5. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Oncology Centers
5.4 Ophthalmology Centers
5.5 Research & Diagnostic Laboratories
6. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size, Comparisons And Growth Rate Analysis
7.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.9. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Immuno-Oncology Drugs, Anti-Angiogenic Agents, Other Monoclonal Antibodies
10. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional And Country Analysis
10.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
12.1. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.1. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
14.1. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
15.1. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
16.1. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
17.1. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
19.1. South East Asia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
20.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
21.1. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
23.1. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
27.1. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
28.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
29.1. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
31.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
32.1. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
34.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
